EDIT
Price
$2.81
Change
-$0.07 (-2.43%)
Updated
Jul 14, 03:36 PM (EDT)
Capitalization
241.09M
16 days until earnings call
MNKD
Price
$3.98
Change
+$0.21 (+5.57%)
Updated
Jul 14, 04:14 PM (EDT)
Capitalization
1.15B
23 days until earnings call
Interact to see
Advertisement

EDIT vs MNKD

Header iconEDIT vs MNKD Comparison
Open Charts EDIT vs MNKDBanner chart's image
Editas Medicine
Price$2.81
Change-$0.07 (-2.43%)
Volume$15.3K
Capitalization241.09M
MannKind
Price$3.98
Change+$0.21 (+5.57%)
Volume$232
Capitalization1.15B
EDIT vs MNKD Comparison Chart in %
Loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EDIT vs. MNKD commentary
Jul 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and MNKD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2025
Stock price -- (EDIT: $2.88 vs. MNKD: $3.77)
Brand notoriety: EDIT and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 89% vs. MNKD: 72%
Market capitalization -- EDIT: $241.09M vs. MNKD: $1.15B
EDIT [@Biotechnology] is valued at $241.09M. MNKD’s [@Biotechnology] market capitalization is $1.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $318.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileMNKD’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • MNKD’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than MNKD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while MNKD’s TA Score has 5 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 4 bearish.
  • MNKD’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, MNKD is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а +12.06% price change this week, while MNKD (@Biotechnology) price change was +4.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +13.15%. For the same industry, the average monthly price growth was +23.60%, and the average quarterly price growth was +32.61%.

Reported Earning Dates

EDIT is expected to report earnings on Nov 10, 2025.

MNKD is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+13.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNKD($1.15B) has a higher market cap than EDIT($241M). EDIT YTD gains are higher at: 126.772 vs. MNKD (-41.369). MNKD has higher annual earnings (EBITDA): 82.6M vs. EDIT (-244.52M). EDIT has more cash in the bank: 221M vs. MNKD (182M). EDIT has less debt than MNKD: EDIT (31.1M) vs MNKD (47.2M). MNKD has higher revenues than EDIT: MNKD (298M) vs EDIT (35.8M).
EDITMNKDEDIT / MNKD
Capitalization241M1.15B21%
EBITDA-244.52M82.6M-296%
Gain YTD126.772-41.369-306%
P/E RatioN/A37.70-
Revenue35.8M298M12%
Total Cash221M182M121%
Total Debt31.1M47.2M66%
FUNDAMENTALS RATINGS
EDIT vs MNKD: Fundamental Ratings
EDIT
MNKD
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
47
Fair valued
PROFIT vs RISK RATING
1..100
10061
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3586
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (42) in the Biotechnology industry is in the same range as MNKD (47). This means that EDIT’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Profit vs Risk Rating (61) in the Biotechnology industry is somewhat better than the same rating for EDIT (100). This means that MNKD’s stock grew somewhat faster than EDIT’s over the last 12 months.

EDIT's SMR Rating (99) in the Biotechnology industry is in the same range as MNKD (100). This means that EDIT’s stock grew similarly to MNKD’s over the last 12 months.

EDIT's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for MNKD (86). This means that EDIT’s stock grew somewhat faster than MNKD’s over the last 12 months.

MNKD's P/E Growth Rating (98) in the Biotechnology industry is in the same range as EDIT (100). This means that MNKD’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITMNKD
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
77%
Momentum
ODDS (%)
N/A
Bullish Trend 4 days ago
83%
MACD
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
77%
Advances
ODDS (%)
Bullish Trend 6 days ago
77%
Bullish Trend 6 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 4 days ago
85%
Aroon
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GICPX62.93-0.26
-0.41%
Gabelli Global Growth AAA
CBSAX26.09-0.12
-0.46%
Columbia Select Mid Cap Growth Fund A
SRICX11.89-0.08
-0.67%
Gabelli SRI C
TESRX26.05-0.18
-0.69%
Franklin Mutual Shares R
LGOQX24.32-0.17
-0.69%
Lord Abbett Growth Opportunities R2

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRSP. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-5.88%
CRSP - EDIT
55%
Loosely correlated
-3.73%
AXON - EDIT
52%
Loosely correlated
-0.46%
VCYT - EDIT
49%
Loosely correlated
-1.60%
NTLA - EDIT
49%
Loosely correlated
-5.14%
PRME - EDIT
49%
Loosely correlated
-7.25%
More